Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721132 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
A Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT04721132: Active Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8, sponsored by M.D. Anderson Cancer Center.
NCT04721132 is a Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants, below the 47-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04721132, a Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.
Primary Outcome
Will estimate pCR rate along with the 95% credible interval.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- PROCEDURE Therapeutic Conventional Surgery
- BIOLOGICAL Bevacizumab
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04721132 still lists
NCT04721132 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 47-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (66% lower).
The record links to 5 conditions, with Resectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT04721132 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04721132 about?
NCT04721132 is a clinical study titled "Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer". This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may inter...
What is the current status of trial NCT04721132?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-02-10. Estimated completion is 2027-12-31.
What conditions does trial NCT04721132 study?
This clinical trial studies the following conditions: Resectable Hepatocellular Carcinoma, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8.
What interventions are being tested in trial NCT04721132?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Therapeutic Conventional Surgery (PROCEDURE), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04721132?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04721132 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SIRT With Tremelimumab and Durvalumab for Resectable HCC
RECRUITING · Phase 1
-
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
RECRUITING · Phase 1
-
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
ACTIVE NOT RECRUITING
-
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI